by Stacey Johnson | Sep 4, 2026
Two articles in an August issue of The Globe and Mail caught my attention. The articles were very different – one was in the news section and one was in business – but they converged on a similar theme: women’s health. Women’s health has been under-researched,...
by Stacey Johnson | Jul 23, 2026
“Regulatory approval does not translate to dollars for a company, nor does it lead to patients being treated. Without reimbursement, all of the efforts of translation and development are lost.” My former colleague, Mark Curtis, wrote these words back when he blogged...
by Lyla El-Fayomi | Jun 24, 2026
Patients diagnosed with degenerative eye disorders, such as retinitis pigmentosa (RP) or choroideremia, face a gradual loss of light-sensing cells that eventually leads to blindness. Historically, most treatments could only aim to slow disease progression; however,...
by Sanat Khanna | May 12, 2026
Cell therapy manufacturing generates large volumes of process data – from sensors, bioreactors, quality controls and genomic assays. In many facilities, much of that data are collected for regulatory compliance rather than for process improvement – a pattern that...
by Laya Kiani | Feb 12, 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup...
Comments